In addition, because they lacked co-localized priming antigens, EGFRvIII synNotch-EphA2/IL13R2 CAR-T cells were able to efficiently and completely eliminate GBM tumors without destroying surrounding normal tissue or EphA2 or IL13R2-positive cells elsewhere in the body. This evidence concerns the gene EPHA2 and glioblastoma.